Qiagen NV
qiagen.comHow Do They Make Money?
FY2025 revenue by product or service
revenue
Revenue, FY2025
$2.1B
Sources
-
20-F for FY2025, filed Mar 20, 2026
$2.1B ↗
| Segment | Share | Revenue |
|---|---|---|
|
Consumables and related revenues
|
90% |
Consumables and related revenues, FY2025
$1.9B Sources
|
|
Instruments
|
10% |
Instruments, FY2025
$213.6M Sources
|
|
Sample technologies
|
32%
FY2022: 37%
|
Sample technologies, FY2025
$661.3M Sources
|
|
Diagnostic solutions
|
38%
FY2022: 31%
|
Diagnostic solutions, FY2025
$803.1M Sources
|
|
PCR/Nucleic acid amplification
|
15%
FY2022: 18%
|
PCR/Nucleic acid amplification, FY2025
$309M Sources
|
|
Genomics/NGS
|
12%
FY2022: 11%
|
Genomics/NGS, FY2025
$241.8M Sources
|
|
Other
|
3.6%
FY2022: 3.2%
|
Other, FY2025
$74.9M Sources
|
Do Revenues Turn Into Profits?
Yes. It kept 20 cents of every revenue dollar as net income in FY2025 and turned 22 cents into free cash flow.
Operating income, FY2025
Sources
20-F for FY2025, filed Mar 20, 2026
$465.9MView ↗
▲ +377%
vs FY2024 ($97.7M, 5%)
Net income, FY2025
Sources
20-F for FY2025, filed Mar 20, 2026
$424.9MView ↗
▲ +408%
vs FY2024 ($83.6M, 4%)
Free cash flow, FY2025
Sources
20-F for FY2025, filed Mar 20, 2026
$453.3MView ↗
▼ −10%
vs FY2024 ($506.4M, 26%)
How Are They Changing?
Flat. Revenue was $2.1B in FY2025, about the same as the $2.3B of FY2021.
Revenue over time
Consumables and related revenues
Instruments
Sample technologies
Diagnostic solutions
PCR/Nucleic acid amplification
Genomics/NGS
Other
$2.5B$1.3B$0
$850.6M
$638.8M
$434M
$796.9M
$660.9M
$390.8M
$1.7B
$1.8B
$748.9M
$1.9B
$803.1M
100%50%0%
38%
28%
19%
37%
31%
18%
88%
34%
35%
89%
32%
38%
90%
32%
38%
Loading...
Comments
